Datum Källa Rubrik Typ Alternativ
2022-04-28 Enzymatica Bulletin from Annual General Meeting of Enzymatica AB (publ) on 28 April 2022 Pressreleaser Visa Stäng
2022-04-28 Enzymatica Kommuniké från årsstämma i Enzymatica AB (publ) den 28 april 2022 Pressreleaser Visa Stäng
2022-04-28 Enzymatica Enzymatica AB: Interim report Q1/2022: Our financial targets remain in place Rapporter Ladda ner | Visa Stäng
2022-04-28 Enzymatica Enzymatica AB: Kvartalsrapport Q1/2022: Våra finansiella mål ligger fast Rapporter Ladda ner | Visa Stäng
2022-04-11 Enzymatica Enzymatica AB: Article about ColdZyme acquitted from suspicions of research misconduct Pressreleaser Ladda ner | Visa Stäng
2022-04-11 Enzymatica Enzymatica AB: Artikel om ColdZyme-studie frias från misstankar om oredlighet i forskning Pressreleaser Ladda ner | Visa Stäng
2022-04-04 Enzymatica Enzymatica AB: Enzymatica's mouth spray to be launched in Turkey Pressreleaser Ladda ner | Visa Stäng
2022-04-04 Enzymatica Enzymatica AB: Enzymaticas munspray lanseras i Turkiet Pressreleaser Ladda ner | Visa Stäng
2022-03-31 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisning för 2021 Rapporter Ladda ner | Visa Stäng
2022-03-31 Enzymatica Enzymatica AB: Enzymatica publishes annual report for 2021 Rapporter Ladda ner | Visa Stäng
2022-03-28 Enzymatica Notice of Annual General Meeting 2022 in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-03-28 Enzymatica Kallelse till årsstämma 2022 i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-03-03 Enzymatica Enzymatica AB: Enzymatica's mouth spray to be launched in Mexico Pressreleaser Ladda ner | Visa Stäng
2022-03-03 Enzymatica Enzymatica AB: Enzymaticas munspray lanseras i Mexiko Pressreleaser Ladda ner | Visa Stäng
2022-02-17 Enzymatica Enzymatica AB: Bokslutskommuniké: Tydliga tecken på gynnsamma trender i marknaden efter ett utmanande 2021 Rapporter Ladda ner | Visa Stäng
2022-02-17 Enzymatica Enzymatica AB: Year-end report: Clear signs of favourable market trends after a challenging 2021 Rapporter Ladda ner | Visa Stäng
2022-01-13 Enzymatica Enzymatica AB: BioStock: 2021 lade grunden för Enzymaticas fortsatta expansion Pressreleaser Visa Stäng
2022-01-12 Enzymatica Enzymatica AB: Enzymatica kommenterar felaktiga formuleringar i Dagens Medicin Pressreleaser Ladda ner | Visa Stäng
2022-01-12 Enzymatica Enzymatica AB: Enzymatica comments on wrongful wording in Dagens Medicin Pressreleaser Ladda ner | Visa Stäng
2021-11-26 Enzymatica Enzymatica AB: BioStock: Enzymaticas vd förutspår en spännande framtid Pressreleaser Visa Stäng
2021-11-04 Enzymatica Enzymatica AB: BioStock: Enzymatica ska omsätta 600 Mkr år 2026 Pressreleaser Visa Stäng
2021-11-02 Enzymatica Enzymatica AB: THE LONG-TERM PLAN REMAINS IN CHALLENGING TIMES Rapporter Ladda ner | Visa Stäng
2021-11-02 Enzymatica Enzymatica AB: DEN LÅNGSIKTIGA PLANEN STÅR FAST I EN UTMANANDE TID Rapporter Ladda ner | Visa Stäng
2021-11-02 Enzymatica Enzymatica AB: Enzymaticas styrelse fastställer finansiella mål Pressreleaser Ladda ner | Visa Stäng
2021-11-02 Enzymatica Enzymatica AB: Enzymatica Board decides on financial targets Pressreleaser Ladda ner | Visa Stäng
2021-10-18 Enzymatica Kommuniké från extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-10-18 Enzymatica Bulletin from the extraordinary general meeting in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-09-29 Enzymatica Kallelse till extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-09-29 Enzymatica Notice of extraordinary general meeting in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 29 Sep 2021 | Enzymatica

Notice of extraordinary general meeting in Enzymatica AB (publ)

general meeting (Sw. extra bolagsstämma) to be held on Monday 18 October 2021.

In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the board of directors has resolved that the meeting will be held only by advance voting (postal vote) in accordance with temporary legislation. This means that the meeting will be conducted without the physical presence of shareholders, proxies or external parties and that shareholders’ exercise of voting rights at the meeting can only take place by advance shareholders voting in the order prescribed below. Information on the resolutions passed by the meeting will be published on Monday 18 October 2021, as soon as the outcome of the advance voting is finally compiled.

Right to participate and notice of participation

Shareholders wishing to participate in the meeting by advance voting must:

  • be registered in the company’s share register kept by Euroclear Sweden AB (the Swedish Securities Register Center) as of Friday 8 October 2021; and
  • have notified their participation no later than Friday 15 October 2021 by casting their advance vote to the company in accordance with the instructions under the heading ”Voting in advance” below so that the advance vote is received by the company no later than that day.

Trustee-registered shares

Shareholders whose shares are trustee-registered in the name of a bank or other trustee must request the trustee to register their shares in their own name with Euroclear Sweden AB (so called ”voting rights registration”), to be able to exercise their voting rights at the meeting by advance voting. Such voting rights registration must be implemented by the trustee no later than Tuesday 12 October 2021. In advance of this date, shareholders must notify their trustee of their request of such voting rights registration.

Voting in advance

Shareholders may exercise their voting rights at the meeting only by voting in advance, so called postal voting in accordance with Section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations. A special form shall be used for advance voting. The form is available on the company’s website (www.enzymatica.com). The advance voting form is considered as the notification of attendance to the meeting. The completed voting form must be submitted to the company no later than Friday 15 October 2021. The completed and signed form shall be sent to Enzymatica AB (publ), Ideon Science Park, Scheelevägen 19, SE-223 70 Lund, Sweden (mark the envelope ”Postal voting extraordinary general meeting 2021”). A completed form may also be submitted electronically and is to be sent to louise.forssell@enzymatica.com.If a shareholder votes in advance through a proxy, a written and dated power of attorney signed by the shareholder must be attached to the form. A proxy form is available on the company’s website (www.enzymatica.com). If the shareholder is a legal entity, a registration certificate or equivalent document shall be enclosed to the form. The shareholder may not provide special instructions or conditions in the voting form. If so, the vote will be invalid. Further instructions and conditions are included in the advance voting form.

Proposed agenda

1. Opening of the meeting.
2. Election of chairman of the meeting.
3. Election of one or two persons to verify the minutes.
4. Preparation and approval of the voting list.
5. Approval of the agenda.
6. Consideration as to whether the meeting has been duly convened.
7. Resolution on implementation of an incentive program for CEO by way of (a) employee option program; and (b) directed issue of warrants and approval of transfer of warrants.
8. Closing of the meeting.

Resolution proposals

Item 2: Election of chairman of the meeting

The board of directors proposes that the chairman of the board Bengt Baron is elected as chairman of the meeting, or, in his absence, the person appointed by the board of directors instead.

Item 3: Election of one or two persons to verify the minutes

Therese Filmersson is proposed to, together with the chairman, verify the minutes of the meeting, or, in her absence, the person appointed by the board of directors instead. The assignment to verify the minutes also includes controlling the voting list and that received advance votes are correctly reproduced in the minutes.

Item 4: Preparation and approval of the voting list

The voting list that is proposed to be approved is the voting list prepared by the company, based on the share register of the meeting and received advance votes, controlled by the person verifying the minutes of the meeting.

Item 7: Resolution on implementation of an incentive program for CEO by way of (a) employee option program; and (b) directed issue of warrants and approval of transfer of warrants

The board of directors proposes that the meeting resolves to implement an incentive program for the company’s new CEO Claus Egstrand based on issuance of employee options, directed issue of warrants and approval of transfer of warrants (the ”Employee Option Program 2021”), on the following terms and conditions.

A. The board’s proposal for resolution on implementation of Employee Option Program 2021

The board of directors’ proposes that the extraordinary general meeting resolves on the implementation of the Employee Option Program 2021 on mainly the following terms:

1. The Employee Option Program 2021 shall comprise a maximum of 250,000 employee options.
2. Each employee option entitles the holder to purchase one new share in the company at a subscription price amounting to 150 per cent of the volume weighted average price according to Nasdaq First North Growth Market’s official price list for shares in the company during the period as from and including 19 October 2021 to and including 1 November 2021. The subscription price shall be rounded to the whole öre, whereupon 0.5 öre shall be rounded upwards. The subscription price and the number of shares that each employee option entitles right to may be subject to recalculation in the event of a bonus issue, split, rights issue etc., whereby the recalculation terms in the complete terms and conditions of the warrants shall be applied.
3. The Employee Option Program 2021 shall comprise the company’s CEO.
4. Allotment shall take place no later than one month from the issue resolution.
5. The allotted employee options shall vest with 1/3 each on 31 October 2022, 31 October 2023 and 31 October 2024. The number of vested employee options at each vesting date shall be rounded downwards to the closest whole number and any excessive employee options will only be vested at the last vesting date.
6. Vesting is conditional upon that the participant continues to be employed within the company or another company in the group in which the company is the parent company (the ”Group”) and has not terminated the employment as of the date when the respective vesting occurs. If the participant ceases to be employed or terminates its employment within the Group before a vesting date, the already vested employee options may be exercised on the ordinary date of exercise in accordance with the below, but further vesting will not occur. However, if the participant’s employment is terminated due to dismissal or due to breach of contract or similar, vested employee options shall also lapse.
7. In the event of a public take-over offer, asset sale, liquidation, merger or any other such transaction affecting the company, the employee options will vest in their entirety and be exercisable in connection with the relevant transaction.
8. The employee options shall not constitute securities and shall not be able to be transferred or pledged. However, in the event of death, the rights constituted by the employee options shall accrue to the beneficiaries of the holder of the employee options.
9. The employee options shall be transferred to the participant for a cash payment equivalent to the market value of the warrants which are to be issued in accordance with section B below, calculated in accordance with the Black Scholes formula. The calculation of the market value of the warrants will be carried out by Öhrlings PricewaterhouseCoopers AB in connection with the expiry of the measurement period on 1 November 2021. The payment shall be submitted in connection with the allotment of employee options.
10. Allotted and vested employment options can only be exercised during the period from and including 15 November 2024 to and including 31 December 2024.
11. Participation in the Employee Option Program 2021 requires that such participation is in accordance with applicable laws, as well as that such participation can take place with reasonable administrative costs and financial efforts according to the company’s opinion.
12. The employee options shall be governed by separate agreements with the participant. The board of directors shall be responsible for the preparation and management of the Employee Option Program 2021 within the above mentioned substantial terms and guidelines.

B. The board of directors’ proposal to resolution on a directed issue of warrants and approval of transfer of warrants

In order to enable the company’s delivery of shares under Employee Option Program 2021, the board of directors proposes that the extraordinary general meeting resolves on a directed issue of warrants and approval of transfer of warrants. The board of directors thus proposes that the extraordinary general meeting resolves on an issue of warrants in accordance with the following terms and conditions:

1. A maximum of 250,000 warrants shall be issued for the Employee Option Program 2021.
2. With deviation from the shareholders’ preferential rights, the right to subscribe shall vest in the company’s wholly owned subsidiary, Enzymatica Care AB, Reg. No. 556701-7495 (the ”Subsidiary”). The reason for the deviation from the shareholders’ preferential rights is that the warrants shall be used within the Employee Option Program 2021.
3. Subscription of the warrants shall be made on a designated subscription list within one month from the issue resolution. The board of directors have the right to prolong the subscription period.
4. Over subscription cannot occur.
5. The warrants shall be issued to the Subsidiary for a cash payment equivalent to the market value of the warrants calculated in accordance with the Black Scholes formula. The calculation of the market value of the warrants will be carried out by Öhrlings PricewaterhouseCoopers AB in connection with the expiry of the measurement period on 1 November 2021. The payment shall be submitted in connection with subscription.
6. Each warrant shall entitle to subscription of one (1) share in the company.
7. Subscription of shares by virtue of the warrants may be effected during the period as from registration with the Companies Registration Office up to and including 31 December 2024.
8. The subscription price per share shall correspond to 150 per cent of the volume weighted average price according to Nasdaq First North Growth Market’s official price list for shares in the company during the period as from and including 19 October 2021 to and including 1 November 2021. The subscription price shall be rounded to the whole öre, whereupon 0.5 öre shall be rounded upwards. The amount that exceeds the share quotient value shall be added to the free share premium reserve. The subscription price and the number of shares that each warrant entitles right to subscribe for shall be subject to customary recalculation upon split-up or consolidation of shares, rights issue or similar events.
9. A share issued after subscription confers the right to dividend the first time on the record date for dividends that occurs immediately following effectuation of subscription to such extent that the share has been recorded in the company’s share ledger as interim share.
10. In case all warrants are utilized for subscription of new shares, the share capital will increase with SEK 10,000.01.

The board of directors further proposes that the extraordinary general meeting shall resolve to approve that the Subsidiary may transfer warrants to the participant in the Employee Option Program 2021 without consideration in connection with the exercise of employee options in accordance with the terms and conditions under Section A or otherwise dispose over the warrants to secure the company’s commitments in relation to the Employee Option Program 2021.

Other information regarding Employee Option Program 2021

The reasons for the implementation of the Employee Option Program 2021 and the deviation from the shareholders’ preferential rights is that the board of directors considers that an employee option program that gives the participant the opportunity to take part in the company’s long-term performance promotes participation and responsibility and provides increased motivation and loyalty to work for a favorable economic development in the company. The Employee Option Program 2021 is also expected to contribute to the opportunities to recruit and retain competent, motivated and engaged co-workers as well as to the fulfillment of the company’s business strategy, long-term interests and sustainability.

The reason why the Employee Option Program 2021 includes only one participant is that the employee stock options are issued within the framework of an EMI (Enterprise Management Incentive) plan to the company’s new CEO, who is resident in the United Kingdom. As the participant is liable to tax in the United Kingdom, it has been considered beneficial for the participant and the company to provide the participant with the opportunity to take part in the Employee Option Program 2021. Furthermore, the participant will be provided with the opportunity to acquire 250,000 of the 500,000 warrants which were reserved for the company’s CEO during the warrant program resolved upon at the annual general meeting on 5 May 2021 (”Warrant Program 2021/2024”). Such warrants earmarked for the company’s CEO under the Warrants Program 2021/2024 have earlier neither been subscribed nor allotted, whereas all 500,000 warrants reserved for the CEO remains to be distributed at the time of the extraordinary general meeting. The remaining 250,000 warrants in Warrant Program 2021/2024 reserved for the company’s CEO, and which are not acquired by the participant, will neither be subscribed nor allotted.

The board of directors makes the assessment that the Employee Option Program 2021 will incur costs in the form of accountancy-based personnel costs. Applicable accounting rules state that the employee options shall be expensed as personnel costs over the vesting period and will be accounted for directly against equity. The accountancy-based personnel costs do not affect the company’s cash flow. Since the participant in the Employee Option Program 2021 is employed in the UK, the board of directors does not consider that the Employee Option Program 2021 will incur any social costs.

The employee options do not have a market value since they are not transferable. However, the board of directors has calculated a theoretical value of the employee options using the Black Scholes formula. Assuming a share price at the time of allocation of the options of SEK 10.30 and that 100 per cent of the options are vested, the total accountancy-based cost for the Employee Option Program 2021 is estimated, in accordance with the Black Scholes formula (assuming a volatility of 88 per cent), to be approximately SEK 1,187,357 before tax during the period 2021-2024.

It shall be noted that the calculations above are based on preliminary assumptions and are only intended to provide an illustration of the outcome.

As of the date of the notice, the number of shares in the company amounts to 149,324,400. In case all 250,000 employee options issued within the Employee Option Program 2021 are utilized for subscription of new shares, a total of 250,000 new shares will be issued, which corresponds to a dilution of approximately 0.17 per cent of the company’s current share capital and votes after full dilution. The dilution would only have a marginal impact on the company’s key figures ”Earnings per share” for the full year 2020.

Since previously, the company has four outstanding warrants programs in the form of two personnel option programs, Personnel Option Program 2017/2023 I and Personnel Option Program 2017/2023 II, resolved at the annual general meeting 2017 and by the extraordinary general meeting in October 2017 (together the ”Personnel Option Programs”), and two warrant programs, resolved at the annual general meeting 2020 and at the annual general meeting 2021 (the ”Warrant Programs”). The Personnel Option Programs comprise a total of 3,740,000 personnel options, whereby 4,915,108 warrants have been issued to the Subsidiary to secure delivery of shares and to secure social security contributions. Within the framework of the Warrant Programs, a maximum of 3,800,000 warrants could be issued in accordance with the resolutions of the annual general meetings. However, only 1,204,350 warrants have been subscribed and allotted. As stated above, 250,000 warrants under the Warrant Program 2021/2024 will at the same time be acquired by the participant in Personnel Option Program 2021. In summary, this means that the additional maximum of 2,345,650 warrants that could be issued have never been subscribed and allotted, nor will they be subscribed and allotted before the extraordinary general meeting. Consequently, these 2,345,650 warrants are not included in the dilution calculations below. For the avoidance of any misunderstandings, this means that the maximum dilution that may arise when exercising all warrants issued, subscribed and allotted in the Warrant Programs or proposed to be issued under Employee Options Program 2021, entails a lower total dilution than the maximum dilution that could have occurred if all 3,800,000 warrants that could be issued in the Warrant Programs had been subscribed and allotted.

Each warrant in the Personnel Option Programs entitles to subscription of 1.03 new shares and each warrant in the Warrant Programs entitles to subscription of one new share in the company. The Personnel Option Programs lapse in August 2023 and the Warrant Programs lapse in September 2023 and September 2024 respectively.

If all of the warrants issued in the Personnel Option Programs and the Warrant Programs are exercised for subscription of new shares, a total of 4,941,161 new shares will be issued, corresponding to a dilution of approximately 3.20 per cent of the company’s current share capital and votes after full dilution. In case all outstanding warrants in the Personnel Option Programs, Warrant Programs, as well as the warrants proposed to be issued under Employee Option Program 2021, are utilized, a total of 5,191,161 shares will be issued, which corresponds to a dilution of approximately 3.36 per cent of the company’s current share capital and votes after full dilution.

The above calculations regarding dilution and effect on kay ratio are subject to recalculation of the warrants in accordance with the customary recalculation terms included in the complete terms and conditions for the warrants.

The board of director’s proposal of the Employee Option Program 2021 has been prepared by the remuneration committee together with external consultants. The final proposal has been resolved upon by the board of directors.

The extraordinary general meeting’s resolution in accordance with the board of directors’ proposal under Sections A-B above shall be resolved upon as one resolution. A valid resolution requires that the proposal is supported by shareholders representing more than nine-tenths (9/10) of the votes cast as well as the shares represented at the meeting.

The board of directors, or anyone appointed by the board of directors, shall be authorized to make the minor adjustments of the meeting’s resolution alongside with appendixes, which may be required in connection with the registration with the Swedish Companies Registration Office (Sw. Bolagsverket) and Euroclear Sweden AB.

Shareholders’ right to information

The board of directors and the CEO shall, if any shareholder so requests and the board of directors believes that it can be done without significant harm to the company, provide information regarding circumstances that may affect the assessment of an item on the agenda. Requests for such information must be submitted via e-mail to louise.forssell@enzymatica.comor by post to Enzymatica AB (publ), Ideon Science Park, Scheelevägen 19, SE-223 70 Lund, Sweden (mark the envelope ”Information extraordinary general meeting 2021”), no later than Friday 8 October 2021. The information is provided by keeping it available at the company’s office and website, no later than Wednesday 13 October 2021. The information will also be sent within the same time to the shareholders who have requested it and provided their postal or e-mail address.

Meeting documents

The complete proposals for resolutions and other documents for the meeting, are presented by keeping them available at the company’s office at Ideon Science Park, Scheelevägen 19, SE-223 70 Lund, Sweden and at the company’s website (www.enzymatica.com) as from no later than two weeks prior to the meeting, and will also be sent to shareholders who request it and provide their postal address. The share register of the meeting will also be available at the company’s office.

Number of shares and votes in the company

The total number of shares and votes in the company amounts to 149,324,400. The company does not hold any own shares.

Processing of personal data

For information on how your personal data is processed, see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. 

____________________

Lund in September 2021

Enzymatica AB (publ)

The Board of Directors

For more information, please contact

Bengt Baron, Chairman, Enzymatica AB
Phone: +46 (0)708-59 30 09 | Email: bengt.baron@outlook.com

Therese Filmersson, CFO, Enzymatica AB
Phone: +46 (0)708-40 72 24 | Email: therese.filmersson@enzymatica.com

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about 30 markets on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases.

Enzymatica’s Certified Adviser is Erik Penser Bank. Phone: +46 (0)8 463 83 00 E-mail: certifiedadviser@penser.se.

2021-09-09 Enzymatica Enzymatica AB: BioStock: Enzymaticas nya vd tillträder tidigare än planerat Pressreleaser Visa Stäng
2021-09-08 Enzymatica Enzymatica AB: Korrigering av tidigare pressmeddelande: Claus Egstrand tillträder som VD tidigare än beräknat Pressreleaser Visa Stäng
2021-09-08 Enzymatica Enzymatica AB: Claus Egstrand takes office as CEO ahead of schedule Pressreleaser Visa Stäng
2021-09-08 Enzymatica Enzymatica AB: Claus Egstrand tillträder som VD tidigare än beräknat Pressreleaser Visa Stäng
2021-08-11 Enzymatica Enzymatica AB: Chinese and US patent authorities issue notices of allowance for patent for key component in cold spray ColdZyme Pressreleaser Ladda ner | Visa Stäng
2021-08-11 Enzymatica Enzymatica AB: Kinesiska och amerikanska patentverken avser att bevilja patent för nyckelkomponent i förkylningsprodukten ColdZyme Pressreleaser Ladda ner | Visa Stäng
2021-07-16 Enzymatica Enzymatica AB: Continued lower sales due to pandemic but some stabilization Rapporter Ladda ner | Visa Stäng
2021-07-16 Enzymatica Enzymatica AB: Fortsatt lägre försäljning till följd av pandemin men viss stabilisering Rapporter Ladda ner | Visa Stäng
2021-07-14 Enzymatica Enzymatica AB: BioStock: Enzymatica utser Claus Egstrand till ny vd Pressreleaser Visa Stäng
2021-07-13 Enzymatica Enzymatica AB: Claus Egstrand appointed new CEO of Enzymatica Pressreleaser Ladda ner | Visa Stäng
2021-07-13 Enzymatica Enzymatica AB: Claus Egstrand utsedd till ny VD för Enzymatica Pressreleaser Ladda ner | Visa Stäng
2021-07-12 Enzymatica Enzymatica AB: Enzymatica och STADA utökar avtalet för ViruProtect till Vietnam Pressreleaser Ladda ner | Visa Stäng
2021-07-12 Enzymatica Enzymatica AB: Enzymatica and STADA extend agreement on ViruProtect to Vietnam Pressreleaser Ladda ner | Visa Stäng
2021-06-29 Enzymatica Enzymatica AB: BioStock: Ny kvalitetschef och kommunikationschef i Enzymatica Pressreleaser Visa Stäng
2021-06-22 Enzymatica Enzymatica AB: Enzymatica appoints new Director of Quality Assurance and Communication Manager Pressreleaser Ladda ner | Visa Stäng
2021-06-22 Enzymatica Enzymatica AB: Enzymatica utser ny kvalitetschef och kommunikationschef Pressreleaser Ladda ner | Visa Stäng
2021-06-08 Enzymatica Enzymatica AB: BioStock: Enzymaticas förkylningsspray lanseras på e-handelsjätten Amazon Pressreleaser Visa Stäng
2021-06-07 Enzymatica Enzymatica AB: Enzymatica announces outcome of new rights issue Pressreleaser Ladda ner | Visa Stäng
2021-06-07 Enzymatica Enzymatica AB: Enzymatica offentliggör utfall i företrädesemissionen Pressreleaser Ladda ner | Visa Stäng
2021-06-03 Enzymatica Enzymatica AB: Enzymatica launches ColdZyme on Amazon Pressreleaser Ladda ner | Visa Stäng
2021-06-03 Enzymatica Enzymatica AB: Enzymatica lanserar ColdZyme på Amazon Pressreleaser Ladda ner | Visa Stäng
2021-05-25 Enzymatica Enzymatica AB: BioStock: Godkänt patent stärker Enzymaticas position i Japan Pressreleaser Visa Stäng
2021-05-21 Enzymatica Enzymatica AB: Patent for ColdZyme approved in Japan Pressreleaser Ladda ner | Visa Stäng
2021-05-21 Enzymatica Enzymatica AB: Patent för ColdZyme godkänt i Japan Pressreleaser Ladda ner | Visa Stäng
2021-05-12 Enzymatica Enzymatica AB: Prospekt avseende Enzymaticas företrädesemission offentliggjort Pressreleaser Ladda ner | Visa Stäng
2021-05-12 Enzymatica Enzymatica AB: Prospectus for Enzymatica's rights issue is published Pressreleaser Ladda ner | Visa Stäng
2021-05-05 Enzymatica Kommuniké från årsstämma i Enzymatica AB (publ) den 5 maj 2021 Pressreleaser Ladda ner | Visa Stäng
2021-05-05 Enzymatica Bulletin from Annual General Meeting of Enzymatica AB (publ) on 5 May 2021 Pressreleaser Ladda ner | Visa Stäng
2021-05-05 Enzymatica Enzymatica AB: BioStock: Enzymaticas Q1-rapport visar att pandemin drabbar försäljningen Pressreleaser Visa Stäng
2021-04-29 Enzymatica Enzymatica AB: Lägre försäljning till följd av pandemin men nyemission säkerställer fortsatt internationell expansion Rapporter Ladda ner | Visa Stäng
2021-04-29 Enzymatica Enzymatica AB: Lower sales due to the pandemic but new rights issue secures continued international expansion Rapporter Ladda ner | Visa Stäng
2021-04-22 Enzymatica Enzymatica AB: BioStock: Enzymaticas styrelseordförande om nyemissionen Pressreleaser Visa Stäng
2021-03-31 Enzymatica Enzymatica AB: Enzymatica Publication of the Annual Report 2020 Rapporter Ladda ner | Visa Stäng
2021-03-31 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisningen för 2020 Rapporter Ladda ner | Visa Stäng
2021-03-31 Enzymatica Kallelse till årsstämma 2021 i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-03-31 Enzymatica Notice of Annual General Meeting 2021 in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2021-03-29 Enzymatica Enzymatica AB: Styrelsen i Enzymatica beslutar om nyemission om 59,1 MSEK Pressreleaser Ladda ner | Visa Stäng
2021-03-29 Enzymatica Enzymatica AB: Enzymatica's Board of Directors decides on a new rights issue of SEK 59.1 million Pressreleaser Ladda ner | Visa Stäng
2021-03-23 Enzymatica Enzymatica AB: BioStock: Enzymatica om minskad försäljning och planerad nyemission Pressreleaser Visa Stäng
2021-03-22 Enzymatica Enzymatica AB: Enzymaticas försäljning och resultat påverkat av pandemin Pressreleaser Ladda ner | Visa Stäng
2021-03-22 Enzymatica Enzymatica AB: Enzymatica's sales and result affected by the pandemic Pressreleaser Ladda ner | Visa Stäng
2021-02-23 Enzymatica Enzymatica AB: BioStock: Enzymatica har bäddat för fortsatt tillväxt Pressreleaser Visa Stäng
2021-02-18 Enzymatica Enzymatica AB: BioStock Studio: Enzymaticas ordförande om framgångarna under 2020 Pressreleaser Visa Stäng
2021-02-18 Enzymatica Enzymatica AB: Positive operating result and almost doubled sales for the fourth quarter Rapporter Ladda ner | Visa Stäng
2021-02-18 Enzymatica Enzymatica AB: Positivt rörelseresultat och nästan fördubblad försäljning för det fjärde kvartalet Rapporter Ladda ner | Visa Stäng
2021-02-11 Enzymatica Enzymatica AB: Enzymatica comments on article in Dagens Medicin Pressreleaser Ladda ner | Visa Stäng
2021-02-11 Enzymatica Enzymatica AB: Enzymatica kommenterar artikel i Dagens Medicin Pressreleaser Ladda ner | Visa Stäng
2021-01-21 Enzymatica Enzymatica AB: BioStock: Enzymaticas starka tillväxt under 2020 Pressreleaser Visa Stäng
2021-01-20 Enzymatica Enzymatica AB: BioStock: Enzymatica stärker organisationen Pressreleaser Visa Stäng
2021-01-15 Enzymatica Enzymatica AB: New strategic recruitments and organizational changes at Enzymatica Pressreleaser Ladda ner | Visa Stäng
2021-01-15 Enzymatica Enzymatica AB: Nya strategiska rekryteringar och organisations-förändring hos Enzymatica Pressreleaser Ladda ner | Visa Stäng
2020-12-10 Enzymatica Enzymatica AB: BioStock: Enzymaticas avtal med STADA utökas till att inkludera Norden Pressreleaser Visa Stäng
2020-12-09 Enzymatica Enzymatica AB: STADA agreement extended for the Nordic Region Pressreleaser Ladda ner | Visa Stäng
2020-12-09 Enzymatica Enzymatica AB: STADA-avtalet utökat med Norden Pressreleaser Ladda ner | Visa Stäng
2020-11-18 Enzymatica Enzymatica AB: BioStock: Enzymatica tecknar distributionsavtal för MENA Pressreleaser Visa Stäng
2020-11-12 Enzymatica Enzymatica AB: Enzymatica ingår avtal med MS Pharma för MENA Pressreleaser Ladda ner | Visa Stäng
2020-11-12 Enzymatica Enzymatica AB: Enzymatica enters agreement with MS Pharma for MENA Pressreleaser Ladda ner | Visa Stäng
2020-11-04 Enzymatica Enzymatica AB: BioStock: Enzymaticas försäljningsutveckling fortsatte i Q3 Pressreleaser Visa Stäng
2020-11-04 Enzymatica Penser Access: Enzymatica - Positivt kassaflöde Pressreleaser Visa Stäng
2020-11-03 Enzymatica Enzymatica AB: Continued strong sales increase and positive cash flow in third quarter Rapporter Ladda ner | Visa Stäng
2020-11-03 Enzymatica Enzymatica AB: Fortsatt stark försäljningsökning samt positivt kassaflöde under det tredje kvartalet Rapporter Ladda ner | Visa Stäng
2020-10-23 Enzymatica Enzymatica AB: BioStock: Enzymatica kommenterar avtalet med Sanofi Pressreleaser Visa Stäng
2020-10-22 Enzymatica Enzymatica AB: BioStock: Enzymaticas Sanofi-avtal öppnar för försäljning av ColdZyme i Italien och Frankrike Pressreleaser Visa Stäng
2020-10-21 Enzymatica Enzymatica AB: Enzymatica ingår avtal med Sanofi gällande Frankrike och Italien för förkylningssprayen ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-10-21 Enzymatica Enzymatica AB: Enzymatica enters agreement with Sanofi for covering France and Italy on common cold spray Coldzyme® Pressreleaser Ladda ner | Visa Stäng
2020-10-14 Enzymatica Enzymatica AB: BioStock: Enzymatica och STADA utökar avtalet för ViruProtect Pressreleaser Visa Stäng
2020-10-13 Enzymatica Enzymatica AB: Enzymatica och STADA utökar avtalet för ViruProtect till Ryssland, Polen, Ukraina och CIS-länder Pressreleaser Ladda ner | Visa Stäng
2020-10-13 Enzymatica Enzymatica AB: Enzymatica and STADA extend agreement on ViruProtect to Russia, Poland, Ukraine and CIS countries Pressreleaser Ladda ner | Visa Stäng
2020-10-07 Enzymatica Enzymatica AB: BioStock: Startskott för försäljning av ColdZyme i Israel Pressreleaser Visa Stäng
2020-10-07 Enzymatica Enzymatica AB: ColdZyme lanserad i Israel Pressreleaser Ladda ner | Visa Stäng
2020-10-07 Enzymatica Enzymatica AB: ColdZyme launched in Israel Pressreleaser Ladda ner | Visa Stäng
2020-09-28 Enzymatica Enzymatica AB: The Journal of Medical Virology has peer reviewed, approved and published the results of Enzymatica's in vitro study on SARS-CoV-2 Pressreleaser Ladda ner | Visa Stäng
2020-09-28 Enzymatica Enzymatica AB: The Journal of Medical Virology har granskat, godkänt och publicerat resultaten från Enzymaticas in vitro-studie på SARS-CoV-2 Pressreleaser Ladda ner | Visa Stäng
2020-09-24 Enzymatica Enzymatica AB: BioStock: Enzymatica erhåller patent på två stora marknader Pressreleaser Visa Stäng
2020-09-23 Enzymatica Enzymatica AB: Nya patent godkända för ColdZyme i Japan och Ryssland Pressreleaser Ladda ner | Visa Stäng
2020-09-23 Enzymatica Enzymatica AB: New patents approved for ColdZyme in Japan and Russia Pressreleaser Ladda ner | Visa Stäng
2020-09-17 Enzymatica Enzymatica AB: Ny version - rättad den 17 september 2020 Resultaten från Enzymaticas placebokontrollerade, randomiserade studie visar statistiskt signifikant kortare förkylningar. Pressreleaser Ladda ner | Visa Stäng
2020-09-17 Enzymatica Enzymatica AB: New version - corrected 17 September, 2020 The results of Enzymatica's placebo-controlled, randomized study Pressreleaser Ladda ner | Visa Stäng
2020-08-26 Enzymatica Enzymatica AB: BioStock: Enzymaticas COO kommenterar årets framgångar Pressreleaser Visa Stäng
2020-08-17 Enzymatica Enzymatica AB: Resultaten från Enzymaticas placebokontrollerade, randomiserade studie visar statistiskt signifikant kortare förkylningar och god upplevd behandlings-effekt vid användning av ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-08-17 Enzymatica Enzymatica AB: The results of Enzymatica's placebo-controlled, randomized study show statistically significant shorter common colds and good treatment efficacy when using ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-07-20 Enzymatica Enzymatica AB: BioStock: ColdZyme kan deaktivera viruset som orsakar Covid-19 Pressreleaser Visa Stäng
2020-07-20 Enzymatica Enzymatica AB: A new in vitro study shows the ability of ColdZyme to deactivate SARS-CoV-2, the cause of the COVID-19 pandemic Pressreleaser Ladda ner | Visa Stäng
2020-07-20 Enzymatica Enzymatica AB: En ny in vitro-studie visar att ColdZyme deaktiverar SARS-Cov-2 som orsakar Covid-19 pandemin Pressreleaser Ladda ner | Visa Stäng
2020-07-17 Enzymatica Enzymatica: Penser Access: Starkt kvartal men under vår förväntan Pressreleaser Visa Stäng
2020-07-16 Enzymatica Enzymatica AB: BioStock: Nytt rekordkvartal för Enzymatica Pressreleaser Visa Stäng
2020-07-16 Enzymatica Enzymatica AB: Fördubblad försäljning även under det andra kvartalet Rapporter Ladda ner | Visa Stäng
2020-07-16 Enzymatica Enzymatica AB: Doubled sales also during the second quarter Rapporter Ladda ner | Visa Stäng
2020-06-05 Enzymatica Enzymatica AB: BioStock: Nya studiedata stärker Enzymaticas case ytterligare Pressreleaser Visa Stäng
2020-06-03 Enzymatica Enzymatica AB: Kortare förkylningar för elitidrottare med ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-06-03 Enzymatica Enzymatica AB: Shorter duration of common colds for endurance athletes with ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-05-27 Enzymatica Penser Access: Enzymatica - STADA växlar upp Pressreleaser Visa Stäng
2020-05-26 Enzymatica Enzymatica AB: BioStock: Nytt distributionsavtal mellan Enzymatica och STADA Pressreleaser Visa Stäng
2020-05-25 Enzymatica Enzymatica AB: Enzymatica och STADA utökar avtalet för Europa Pressreleaser Ladda ner | Visa Stäng
2020-05-25 Enzymatica Enzymatica AB: Enzymatica and STADA extend agreement for Europe Pressreleaser Ladda ner | Visa Stäng
2020-05-19 Enzymatica Enzymatica AB: Grant of European patent for ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-05-19 Enzymatica Enzymatica AB: Europapatent godkänt för ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-05-19 Enzymatica Enzymatica AB: BioStock: Enzymatica skyfflar om bolagsledningen Pressreleaser Visa Stäng
2020-05-18 Enzymatica Enzymatica AB: Changes in management at Enzymatica Pressreleaser Ladda ner | Visa Stäng
2020-05-18 Enzymatica Enzymatica AB: Ledningsförändringar i Enzymatica Pressreleaser Ladda ner | Visa Stäng
2020-05-06 Enzymatica Penser Access: Enzymatica - Fortsatt positiv påverkan från COVID-19 Pressreleaser Visa Stäng
2020-05-05 Enzymatica Bulletin from Annual General Meeting in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-05-05 Enzymatica Kommuniké från årsstämma i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-05-05 Enzymatica Enzymatica AB: BioStock: Enzymatica dubblar intäkterna i Q1 Pressreleaser Visa Stäng
2020-05-05 Enzymatica Enzymatica AB: Fördubblad försäljning och positivt resultat under det första kvartalet Rapporter Ladda ner | Visa Stäng
2020-05-05 Enzymatica Enzymatica AB: Doubled sales and positive earnings for the first quarter Rapporter Ladda ner | Visa Stäng
2020-04-27 Enzymatica Enzymatica AB: BioStock: Enzymatica erhåller den högsta EU-klassningen Pressreleaser Visa Stäng
2020-04-24 Enzymatica Enzymatica AB: ColdZyme re-certified to class III in the EU Pressreleaser Ladda ner | Visa Stäng
2020-04-24 Enzymatica Enzymatica AB: ColdZyme får klass III-godkännande inom EU Pressreleaser Ladda ner | Visa Stäng
2020-04-21 Enzymatica Enzymatica AB: Enzymatica möjliggör poströstning vid årsstämman 2020 Pressreleaser Ladda ner | Visa Stäng
2020-04-21 Enzymatica Enzymatica AB: Enzymatica enables postal voting at the Annual General Meeting 2020 Pressreleaser Ladda ner | Visa Stäng
2020-04-15 Enzymatica Penser Access: Enzymatica - COVID-19 boostar försäljningen Pressreleaser Visa Stäng
2020-04-03 Enzymatica Enzymatica AB: BioStock: Enzymatica rapporterar kraftigt ökad försäljning under 2019 Pressreleaser Visa Stäng
2020-04-03 Enzymatica Notice of annual general meeting 2020 in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-04-03 Enzymatica Kallelse till årsstämma 2020 i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2020-04-02 Enzymatica Enzymatica AB: Enzymatica - publication of the Annual Report 2019 Pressreleaser Ladda ner | Visa Stäng
2020-04-02 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisningen för 2019 Pressreleaser Ladda ner | Visa Stäng
2020-03-27 Enzymatica Enzymatica AB: Enzymatica gets increased sales due to the Corona situation Pressreleaser Visa Stäng
2020-03-27 Enzymatica Enzymatica AB: Enzymatica får ökad försäljning på grund av Coronasituationen Pressreleaser Ladda ner | Visa Stäng
2020-03-24 Enzymatica Enzymatica AB: BioStock: Enzymatica äntrar den israeliska marknaden Pressreleaser Visa Stäng
2020-03-20 Enzymatica Enzymatica AB: Enzymatica tecknar avtal med Chemipal för Israel Pressreleaser Ladda ner | Visa Stäng
2020-03-20 Enzymatica Enzymatica AB: Enzymatica signs agreement with Chemipal for Israel Pressreleaser Ladda ner | Visa Stäng
2020-03-06 Enzymatica Enzymatica AB: BioStock: Användare hindrar förkylning med ColdZyme Pressreleaser Visa Stäng
2020-03-03 Enzymatica Enzymatica AB: Starka resultat från preventiv användning av ColdZyme mot förkylningsvirus Pressreleaser Ladda ner | Visa Stäng
2020-03-03 Enzymatica Enzymatica AB: Strong results from preventive use of ColdZyme against common cold virus Pressreleaser Ladda ner | Visa Stäng
2020-02-14 Enzymatica Penser Access: Enzymatica - Kosmetikaverksamheten drar upp bruttomarginalen Pressreleaser Visa Stäng
2020-02-13 Enzymatica Enzymatica AB: BioStock: Enzymatica gör sitt bästa årsresultat Pressreleaser Visa Stäng
2020-02-13 Enzymatica Enzymatica AB: ColdZyme - third largest cold brand in Sweden Rapporter Ladda ner | Visa Stäng
2020-02-13 Enzymatica Enzymatica AB: ColdZyme - tredje största varumärke i Sverige inom förkylning Rapporter Ladda ner | Visa Stäng
2020-02-03 Enzymatica Enzymatica AB: BioStock: Förlängt patentskydd för Enzymatica Pressreleaser Visa Stäng
2020-02-03 Enzymatica Enzymatica AB: The European Patent Office recommends grant of a new patent covering a key ingredient in ColdZyme against the common cold Pressreleaser Ladda ner | Visa Stäng
2020-02-03 Enzymatica Enzymatica AB: Europeiska patentverket avser att bevilja ett nytt patent för en nyckelkomponent i förkylningsprodukten ColdZyme Pressreleaser Ladda ner | Visa Stäng
2020-01-28 Enzymatica Enzymatica AB: BioStock: Avgående vd tar styrelsepost i Enzymatica Pressreleaser Visa Stäng
2020-01-28 Enzymatica Enzymatica AB: Valberedningen föreslår Fredrik Lindberg till Enzymaticas styrelse Pressreleaser Ladda ner | Visa Stäng
2020-01-28 Enzymatica Enzymatica AB: The Nomination Committee proposes that Fredrik Lindberg is elected to the Board of Directors Pressreleaser Ladda ner | Visa Stäng
2020-01-23 Enzymatica Enzymatica AB: BioStock: Enzymaticas ColdZyme lanseras i Kina via affär värd 92 Mkr Pressreleaser Visa Stäng
2020-01-22 Enzymatica Enzymatica AB: Enzymatica ingår avtal med Keyuan Trade för Kina Pressreleaser Ladda ner | Visa Stäng
2020-01-22 Enzymatica Enzymatica AB: Enzymatica signs agreement with Keyuan Trade for China Pressreleaser Ladda ner | Visa Stäng
2020-01-16 Enzymatica Enzymatica AB: BioStock: Enzymaticas ColdZyme lanseras på en första marknad i Asien Pressreleaser Visa Stäng
2020-01-14 Enzymatica Enzymatica AB: ColdZyme launched in Hong Kong Pressreleaser Ladda ner | Visa Stäng
2020-01-14 Enzymatica Enzymatica AB: ColdZyme lanserad i Hong Kong Pressreleaser Ladda ner | Visa Stäng
2020-01-10 Enzymatica Enzymatica AB: BioStock: Positiva vindar följer Enzymatica in i 2020 Pressreleaser Visa Stäng
2019-12-21 Enzymatica Enzymatica AB: Rättelse: Enzymaticas VD avgår Pressreleaser Visa Stäng
2019-12-21 Enzymatica Enzymatica AB: Enzymaticas VD avgår Pressreleaser Visa Stäng
2019-12-21 Enzymatica Enzymatica AB: Enzymatica's CEO resigns Pressreleaser Visa Stäng
2019-12-13 Enzymatica Enzymatica AB: Enzymatica in agreement for enzyme formulations for the Chinese skin care market Pressreleaser Visa Stäng
2019-12-13 Enzymatica Enzymatica AB: Enzymatica sluter avtal om leverans av enzymformuleringer för den kinesiska hudvårdsmarknaden Pressreleaser Visa Stäng
2019-11-29 Enzymatica Enzymatica AB: BioStock: Enzymaticas VD om det nya avtalet med STADA Pressreleaser Visa Stäng
2019-11-28 Enzymatica Enzymatica AB: Utökat samarbete med STADA i Tyskland Pressreleaser Ladda ner | Visa Stäng
2019-11-28 Enzymatica Enzymatica AB: STADA collaboration expands in Germany Pressreleaser Visa Stäng
2019-11-13 Enzymatica Enzymatica AB: BioStock: Bengt Baron tycker att Enzymatica är på helt rätt bana Pressreleaser Visa Stäng
2019-11-08 Enzymatica Enzymatica AB: BioStock: Enzymaticas vd nöjd med Q3-resultatet Pressreleaser Visa Stäng
2019-11-06 Enzymatica Penser Access: Enzymatica - Ny smak drar upp försäljningen Pressreleaser Visa Stäng
2019-11-05 Enzymatica Enzymatica AB: Mycket stark försäljningsökning under det tredje kvartalet Rapporter Ladda ner | Visa Stäng
2019-11-05 Enzymatica Enzymatica AB: Very strong increase of sales during the third quarter Rapporter Ladda ner | Visa Stäng
2019-10-10 Enzymatica Enzymatica AB: Enzymatica rekryterar ny kvalitetschef Pressreleaser Ladda ner | Visa Stäng
2019-10-10 Enzymatica Enzymatica AB: Enzymatica recruits new Director of Quality Assurance Pressreleaser Ladda ner | Visa Stäng
2019-09-05 Enzymatica Penser Access: Enzymatica - Negativ klinisk studie Pressreleaser Visa Stäng
2019-09-04 Enzymatica Enzymatica AB: Preliminary results of Enzymatica's placebo-controlled, randomized study did not meet the primary end-point Pressreleaser Ladda ner | Visa Stäng
2019-09-04 Enzymatica Enzymatica AB: Preliminära resultat från Enzymaticas placebokontrollerade, randomiserade studie uppfyllde inte det primära målet Pressreleaser Ladda ner | Visa Stäng
2019-08-26 Enzymatica Enzymatica AB: ColdZyme lanseras med ny smak och nya produktpåståenden Pressreleaser Visa Stäng
2019-08-26 Enzymatica Enzymatica AB: ColdZyme launches with new flavor and new product claims Pressreleaser Visa Stäng
2019-07-18 Enzymatica Penser Access: Enzymatica - Sverige visar vägen Pressreleaser Visa Stäng
2019-07-17 Enzymatica Enzymatica AB: God tillväxt under Q2, främst drivet av stark försäljning i Sverige Rapporter Ladda ner | Visa Stäng
2019-07-17 Enzymatica Enzymatica AB: Good growth in Q2, driven mainly by strong sales in Sweden Rapporter Ladda ner | Visa Stäng
2019-06-20 Enzymatica Penser Access: Enzymatica - Avtal med Maren Cosmetics Pressreleaser Visa Stäng
2019-06-19 Enzymatica Enzymatica AB: Enzymatica tecknar kosmetika-avtal till ett värde av 120 MSEK över tre år med tyska bolaget Maren Pressreleaser Ladda ner | Visa Stäng
2019-06-19 Enzymatica Enzymatica AB: Enzymatica signs supply agreement with German cosmetic company Maren, amounting to a value of SEK 120 million over a period of three years Pressreleaser Ladda ner | Visa Stäng
2019-05-08 Enzymatica Enzymatica: Penser Access: Enzymetica - Placebokontrollerad studie full rekryterad Pressreleaser Visa Stäng
2019-05-07 Enzymatica Kommuniké från årsstämma I Enzymatica AB (publ) Pressreleaser Visa Stäng
2019-05-07 Enzymatica Bulletin from Annual General Meeting in Enzymatica AB (publ) Pressreleaser Visa Stäng
2019-05-07 Enzymatica Enzymatica AB: Fortsatt stark tillväxt i Sverige men lägre total försäljning under kvartalet Rapporter Ladda ner | Visa Stäng
2019-05-07 Enzymatica Enzymatica AB: Continued strong growth in Sweden, but lower total sales during the quarter Rapporter Ladda ner | Visa Stäng
2019-05-03 Enzymatica Enzymatica AB: Samtliga patienter rekryterade till Enzymaticas tyska placebokontrollerade multicenterstudie med ColdZyme Pressreleaser Visa Stäng
2019-05-03 Enzymatica Enzymatica AB: All patients enrolled in Enzymatica's German placebo-controlled multicentre study with ColdZyme Pressreleaser Visa Stäng
2019-04-16 Enzymatica Enzymatica AB: Enzymatica's cold spray launched in South Africa Pressreleaser Ladda ner | Visa Stäng
2019-04-16 Enzymatica Enzymatica AB: Enzymaticas förkylningsspray lanserad i Sydafrika Pressreleaser Ladda ner | Visa Stäng
2019-04-05 Enzymatica Enzymatica AB:Kallelse till årsstämma 2019 i Enzymatica AB (publ) Pressreleaser Visa Stäng
2019-04-05 Enzymatica Enzymatica AB:Notice of annual general meeting 2019 in Enzymatica AB (publ) Pressreleaser Visa Stäng
2019-04-01 Enzymatica Enzymatica AB: - Publication of the annual report 2018 Pressreleaser Visa Stäng
2019-04-01 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisningen för 2018 Pressreleaser Visa Stäng
2019-02-20 Enzymatica Penser Access: Enzymatica - 56% försäljningstillväxt i Sverige Pressreleaser Visa Stäng
2019-02-19 Enzymatica Enzymatica AB: Stark försäljning under fjärde kvartalet, men lägre försäljning för helåret 2018 orsakat av restriktioner i Tyskland Pressreleaser Visa Stäng
2019-02-19 Enzymatica Enzymatica AB: Strong sales in the fourth quarter, but lower sales for full-year 2018 driven by restrictions in Germany Pressreleaser Visa Stäng
2019-01-30 Enzymatica Enzymatica AB: Första patienterna inkluderade i stor placebokontrollerad multicenterstudie med ColdZyme Pressreleaser Visa Stäng
2019-01-30 Enzymatica Enzymatica AB: First patients included in large placebo-controlled multicentre study on ColdZyme Pressreleaser Visa Stäng
2019-01-25 Enzymatica Enzymatica AB: Resultat från den tyska multicenterstudien stärker och breddar ColdZymes produktpåståenden Pressreleaser Visa Stäng
2019-01-25 Enzymatica Enzymatica AB: Results from German multicentre study strengthen and broaden ColdZyme's product claims Pressreleaser Visa Stäng
2018-12-02 Enzymatica Enzymatica AB: Enzymatica raises SEK 98.7 million in completed share issue Pressreleaser Visa Stäng
2018-12-02 Enzymatica Enzymatica AB: Enzymatica tillförs 98,7 MSEK efter avslutad nyemission Pressreleaser Visa Stäng
2018-11-12 Enzymatica Enzymatica AB: Prospekt avseende Enzymaticas företrädesemission offentliggjort Pressreleaser Visa Stäng
2018-11-12 Enzymatica Enzymatica AB: Prospectus for Enzymatica's rights issue with preferential rights for existing shareholders published Pressreleaser Visa Stäng
2018-11-05 Enzymatica Enzymatica AB: Kommuniké från extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-11-05 Enzymatica Enzymatica AB: Bulletin from Extraordinary General Meeting in Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-11-02 Enzymatica Enzymatica AB: Enzymatica's rights issue is secured up to 100 percent Pressreleaser Visa Stäng
2018-11-02 Enzymatica Enzymatica AB: Enzymaticas företrädesemission är säkerställd till 100 procent Pressreleaser Visa Stäng
2018-11-01 Enzymatica Penser Access: Enzymatica - Vädret & restriktioner i Tyskland dra ned försäljningen Pressreleaser Visa Stäng
2018-10-31 Enzymatica Enzymatica AB: Genombrottsavtal för Japan och lägre försäljning i Q3 på grund av restriktioner i Tyskland Pressreleaser Visa Stäng
2018-10-31 Enzymatica Enzymatica AB: Breakthrough agreement for Japan and lower sales in Q3 due to restrictions in Germany Pressreleaser Visa Stäng
2018-10-18 Enzymatica Enzymatica AB: Kallelse till extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-10-18 Enzymatica Enzymatica AB: Notice of Extraordinary General Meeting in Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-10-18 Enzymatica Enzymatica AB: Styrelsen i Enzymatica AB beslutar om företrädesemission om 98,7 Mkr Pressreleaser Visa Stäng
2018-10-18 Enzymatica Enzymatica AB: The Board of Directors of Enzymatica AB decides on rights issue of SEK 98.7 million Pressreleaser Visa Stäng
2018-10-18 Enzymatica Enzymatica AB: Enzymatica signs agreement for the Japanese market Pressreleaser Visa Stäng
2018-10-18 Enzymatica Enzymatica AB: Enzymatica tecknar avtal för den japanska marknaden Pressreleaser Visa Stäng
2018-10-01 Enzymatica Enzymatica AB: Significant benefits from ColdZyme in a major German multicenter study evaluating different common cold symptom scales Pressreleaser Visa Stäng
2018-10-01 Enzymatica Enzymatica AB: Signifikanta fördelar med ColdZyme i en stor tysk multicenterstudie för utvärdering av olika skalor för förkylningssymptom Pressreleaser Visa Stäng
2018-08-29 Enzymatica Enzymatica AB: Appeal of court ruling on Enzymatica's cold spray in Germany Pressreleaser Visa Stäng
2018-08-29 Enzymatica Enzymatica AB: Domen mot Enzymaticas förkylningsspray i Tyskland överklagas Pressreleaser Visa Stäng
2018-07-31 Enzymatica Enzymatica AB: Enzymatica sluter avtal om ColdZyme med ABEX Pharmaceuticals för Sydafrika Pressreleaser Visa Stäng
2018-07-31 Enzymatica Enzymatica AB: Enzymatica signs agreement for ColdZyme with ABEX Pharmaceutica (Pty) Ltd for South Africa Pressreleaser Visa Stäng
2018-07-17 Enzymatica Penser Access: Enzymatica - Tidig vår förkortade förkylningssäsongen Pressreleaser Visa Stäng
2018-07-17 Enzymatica Enzymatica AB: Lägre försäljning under Q2 men 31 %-ökning för det första halvåret Pressreleaser Visa Stäng
2018-07-17 Enzymatica Enzymatica AB: Lower sales in Q2 but 31% increase for the first half of the year Pressreleaser Visa Stäng
2018-07-16 Enzymatica Enzymatica AB: Domstolsutslag lägger restriktioner på Enzymaticas förkylningsspray i Tyskland Pressreleaser Visa Stäng
2018-07-16 Enzymatica Enzymatica AB: Court ruling put restrictions on marketing of Enzymatica's cold spray in Germany Pressreleaser Visa Stäng
2018-06-07 Enzymatica Enzymatica AB: Enzymatica säkerställer finansiering av verksamheten Pressreleaser Visa Stäng
2018-06-07 Enzymatica Enzymatica AB: Enzymatica secures funding for operations Pressreleaser Visa Stäng
2018-05-22 Enzymatica Enzymatica AB: Enzymatica sluter avtal med Qualia Pharma för Grekland och Cypern Pressreleaser Visa Stäng
2018-05-22 Enzymatica Enzymatica AB: Enzymatica signs agreement with Qualia Pharma for Greece and Cyprus Pressreleaser Visa Stäng
2018-04-27 Enzymatica Penser Access: Enzymatica - STADA & svenska apotek drar upp försäljningen Pressreleaser Visa Stäng
2018-04-26 Enzymatica Enzymatica AB: Bulletin from annual general meeting 2018 in Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-04-26 Enzymatica Enzymatica AB: Kommuniké från årsstämma 2018 i Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-04-26 Enzymatica Enzymatica AB: Continued growth during the first quarter Pressreleaser Visa Stäng
2018-04-26 Enzymatica Enzymatica AB: Fortsatt tillväxt under det första kvartalet Pressreleaser Visa Stäng
2018-04-11 Enzymatica Enzymatica AB: Nya resultat från Enzymaticas in vitro-studie: ColdZyme inaktiverar även coronavirus Pressreleaser Visa Stäng
2018-04-11 Enzymatica Enzymatica AB: New results from Enzymatica's in vitro study: ColdZyme also deactivates corona virus Pressreleaser Visa Stäng
2018-04-09 Enzymatica Enzymatica AB: Ny ColdZyme-studie på elitidrottare bekräftar förebyggande och förkortande effekt Pressreleaser Visa Stäng
2018-04-09 Enzymatica Enzymatica AB: New ColdZyme study in elite athletes confirms preventive effect and reduced duration of illness Pressreleaser Visa Stäng
2018-03-28 Enzymatica Enzymatica AB: Enzymatica - publication of the annual report 2017 Pressreleaser Visa Stäng
2018-03-28 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisningen för 2017 Pressreleaser Visa Stäng
2018-03-21 Enzymatica Enzymatica AB: Notice of annual general meeting in Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-03-21 Enzymatica Enzymatica AB: Kallelse till årsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2018-02-15 Enzymatica Penser Access: Enzymatica - Uppföljningsorder från STADA drar upp försäljningen Pressreleaser Visa Stäng
2018-02-14 Enzymatica Enzymatica AB: Strong growth and international breakthrough in 2017 Pressreleaser Visa Stäng
2018-02-14 Enzymatica Enzymatica AB: Stark tillväxt och internationellt genombrott under 2017 Pressreleaser Visa Stäng
2017-11-29 Enzymatica Enzymatica AB: Enzymaticas valberedning för årsstämman 2018 utsedd Pressreleaser Visa Stäng
2017-11-29 Enzymatica Enzymatica AB: Enzymatica's Nomination Committee for the Annual General Meeting 2018 appointed Pressreleaser Visa Stäng
2017-11-14 Enzymatica Enzymatica AB: Enzymatica presenterar resultat av studie: ColdZyme har förmåga att oskadliggöra vanliga förkylningsvirus Pressreleaser Visa Stäng
2017-11-14 Enzymatica Enzymatica AB: Enzymatica announces a study showing the ability of ColdZyme to deactivate major common cold viruses Pressreleaser Visa Stäng
2017-11-09 Enzymatica Enzymatica AB: Studie om ColdZyme - Den mest rekommenderade förkylningsprodukten hos apoteken Pressreleaser Visa Stäng
2017-11-09 Enzymatica Enzymatica AB: ColdZyme study - Most recommended cold product at pharmacies Pressreleaser Visa Stäng
2017-11-02 Enzymatica Penser Access: Enzymatica - Rekordförsäljning Pressreleaser Visa Stäng
2017-11-01 Enzymatica Enzymatica AB: Delårsrapport för Enzymatica AB (publ) Januari- September 2017 Rapporter Visa Stäng
2017-11-01 Enzymatica Enzymatica AB: Interim report for Enzymatica AB (publ) January-September 2017 Pressreleaser Visa Stäng
2017-10-25 Enzymatica Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-10-25 Enzymatica Enzymatica AB: Kommuniké från extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-10-18 Enzymatica Enzymatica AB: Fullständiga artikeln från COLDPREV I-studien publicerad - stärker dokumentation för ColdZyme Pressreleaser Visa Stäng
2017-10-18 Enzymatica Enzymatica AB: Complete article from COLDPREV I study published - strengthens documentation for ColdZyme Pressreleaser Visa Stäng
2017-09-25 Enzymatica Enzymatica AB: Kallelse till extra bolagsstämma angående bland annat personaloptionsprogram i Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-09-25 Enzymatica Enzymatica AB: Notice of extraordinary general meeting regarding among other things personnel option program in Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-09-06 Enzymatica Enzymatica rekryterar finanschef Pressreleaser Visa Stäng
2017-09-06 Enzymatica Enzymatica recruits Chief Financial Officer Pressreleaser Visa Stäng
2017-07-20 Enzymatica Penser Access: Enzymatica - Rekordorder från STADA Pressreleaser Visa Stäng
2017-07-20 Enzymatica Enzymatica AB: Fortsatt försäljningsökning och genombrottsorder från STADA Pressreleaser Visa Stäng
2017-07-20 Enzymatica Enzymatica AB: Continued sales growth and breakthrough order from STADA Pressreleaser Visa Stäng
2017-07-18 Enzymatica Enzymatica rekryterar Chief Commercial Officer Pressreleaser Visa Stäng
2017-07-18 Enzymatica Enzymatica recruits Chief Commercial Officer Pressreleaser Visa Stäng
2017-07-14 Enzymatica Enzymatica rekryterar Chief Operating Officer Pressreleaser Visa Stäng
2017-07-14 Enzymatica Enzymatica recruits Chief Operating Officer Pressreleaser Visa Stäng
2017-06-21 Enzymatica A study of elite athletes shows that ColdZyme provides protection as evidenced by fewer sick days and lost training days, as well as improved quality of life Pressreleaser Visa Stäng
2017-06-21 Enzymatica Studie på elitidrottare visar att ColdZyme skyddar genom att ge färre sjuk- och förlorade träningsdagar samt förbättrad livskvalitet Pressreleaser Visa Stäng
2017-06-14 Enzymatica Enzymatica får rekordorder från tyska STADA Pressreleaser Visa Stäng
2017-06-14 Enzymatica Enzymatica receives record order from STADA Arzneimittel AG Pressreleaser Visa Stäng
2017-05-23 Enzymatica Bengt Jöndell fortsätter som t f CFO Pressreleaser Visa Stäng
2017-05-23 Enzymatica Bengt Jöndell continues as acting CFO Pressreleaser Visa Stäng
2017-04-21 Enzymatica Penser Access: Enzymatica - Expansionen fortsätter i Europa Pressreleaser Visa Stäng
2017-04-20 Enzymatica Enzymatica AB: Bulletin from annual general meeting 2017 in Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-04-20 Enzymatica Enzymatica AB: Kommuniké från årsstämma 2017 i Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-04-20 Enzymatica Enzymatica AB: Breakthrough in Germany and continued increase in sales Pressreleaser Visa Stäng
2017-04-20 Enzymatica Enzymatica AB: Genombrott i Tyskland och fortsatt ökande försäljning Pressreleaser Visa Stäng
2017-04-06 Enzymatica Enzymatica AB: Enzymatica - publication of the annual report 2016 Pressreleaser Visa Stäng
2017-04-06 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisningen för 2016 Pressreleaser Visa Stäng
2017-04-05 Enzymatica Enzymatica AB: Completing the Nomination Committee's in Enzymatica AB proposal for AGM 2017 regarding election of auditor Pressreleaser Ladda ner | Visa Stäng
2017-04-05 Enzymatica Enzymatica AB: Completing the Nomination Committee's in Enzymatica AB proposal for AGM 2017 regarding election of auditor Pressreleaser Visa Stäng
2017-04-05 Enzymatica Enzymatica AB: Komplettering av valberedningens i Enzymatica AB förslag inför årsstämman 2017 avseende val av revisor Pressreleaser Visa Stäng
2017-03-21 Enzymatica Enzymatica AB: Notice of annual general meeting in Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-03-21 Enzymatica Enzymatica AB: Kallelse till årsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2017-02-21 Enzymatica Penser Access: Enzymatica - Tar klivet in i Tyskland Pressreleaser Visa Stäng
2017-02-16 Enzymatica Enzymatica AB: Geographic expansion and continued growth in 2016 Pressreleaser Visa Stäng
2017-02-16 Enzymatica Enzymatica AB:Geografisk expansion och fortsatt tillväxt under 2016 Pressreleaser Visa Stäng
2017-02-13 Enzymatica Enzymatica AB: Enzymatica ingår samarbetsavtal med STADA Arzneimittel AG Pressreleaser Visa Stäng
2017-02-13 Enzymatica Enzymatica AB: Enzymatica enters into partnership agreement with STADA Arzneimittel AG Pressreleaser Visa Stäng
2016-12-21 Enzymatica Enzymatica AB: Top-line results of new clinical trial Pressreleaser Ladda ner | Visa Stäng
2016-12-21 Enzymatica Enzymatica AB: Resultat från experimentell förkylningsstudie Pressreleaser Ladda ner | Visa Stäng
2016-12-19 Enzymatica Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2016-12-19 Enzymatica Enzymatica AB: Kommuniké från extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2016-12-01 Enzymatica Enzymatica AB: NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB (publ) Pressreleaser Visa Stäng
2016-12-01 Enzymatica Enzymatica AB: KALLELSE TILL EXTRA BOLAGSSTÄMMA I ENZYMATICA AB (publ) Pressreleaser Visa Stäng
2016-12-01 Enzymatica Enzymatica AB: Extraordinary shareholders' meeting on changes to the board of directors Pressreleaser Visa Stäng
2016-12-01 Enzymatica Enzymatica AB: Extra bolagsstämma om förändringar i styrelsen Pressreleaser Visa Stäng
2016-11-07 Enzymatica Penser Access: Enzymatica - Nya avtal på andra sidan jorden Pressreleaser Visa Stäng
2016-11-03 Enzymatica Enzymatica AB: ColdZyme® sales continue to perform well Pressreleaser Visa Stäng
2016-11-03 Enzymatica Enzymatica AB: Fortsatt god försäljningsutveckling för ColdZyme® Pressreleaser Visa Stäng
2016-11-02 Enzymatica Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health Pressreleaser Visa Stäng
2016-11-02 Enzymatica Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health Pressreleaser Ladda ner | Visa Stäng
2016-11-02 Enzymatica Enzymatica AB: Enzymatica tecknar distributionssavtal med Endeavour Consumer Health för Australien/Nya Zeeland Pressreleaser Visa Stäng
2016-11-02 Enzymatica Enzymatica AB: Enzymatica tecknar distributionssavtal med Endeavour Consumer Health för Australien/Nya Zeeland Pressreleaser Ladda ner | Visa Stäng
2016-08-30 Enzymatica Enzymatica AB: The board of directors in Enzymatica has resolved on a directed share issue of SEK 40.3 million Pressreleaser Visa Stäng
2016-08-30 Enzymatica Enzymatica AB: Styrelsen i Enzymatica beslutar om riktad nyemission om 40,3 miljoner kronor Pressreleaser Visa Stäng
2016-07-25 Enzymatica Penser Access: Enzymatica - 58% tillväxt under Q2 Pressreleaser Visa Stäng
2016-07-18 Enzymatica Enzymatica AB: Excellent volume growth for ColdZyme® Pressreleaser Visa Stäng
2016-07-18 Enzymatica Enzymatica AB: God volymutveckling för ColdZyme® Pressreleaser Visa Stäng
2016-05-25 Enzymatica Kommuniké från årsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2016-05-25 Enzymatica Bulletin from the Annual General Meeting in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2016-05-11 Enzymatica Enzymatica's new rights issue completed - will be provided with SEK 60 million Pressreleaser Visa Stäng
2016-05-11 Enzymatica Enzymaticas företrädesemission avslutad - tillförs 60 MSEK Pressreleaser Visa Stäng
2016-05-03 Enzymatica Enzymaticas insynspersoner avser teckna för 16 MSEK i nyemissionen Pressreleaser Visa Stäng
2016-05-03 Enzymatica Enzymatica insiders plan to subscribe for SEK 16 million in new issue Pressreleaser Visa Stäng
2016-04-26 Enzymatica Kallelse till årsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2016-04-26 Enzymatica Notice of annual general meeting in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2016-04-20 Enzymatica EP Access: Enzymatica - Nya marknader levererar Pressreleaser Visa Stäng
2016-04-20 Enzymatica Enzymatica publishes prospectus Pressreleaser Visa Stäng
2016-04-20 Enzymatica Enzymatica publicerar prospekt Pressreleaser Ladda ner | Visa Stäng
2016-04-20 Enzymatica Enzymatica publicerar årsredovisningen för 2015 Pressreleaser Visa Stäng
2016-04-20 Enzymatica Enzymatica - publication of the annual report 2015 Pressreleaser Visa Stäng
2016-04-18 Enzymatica Interim Report for Enzymatica AB (publ) January-March 2016 Rapporter Visa Stäng
2016-04-18 Enzymatica Delårsrapport för Enzymatica AB (publ) januari-mars 2016 Rapporter Visa Stäng
2016-04-14 Enzymatica Kommuniké från extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2016-04-14 Enzymatica Bulletin from the extraordinary shareholders' meeting in Enzymatica Pressreleaser Visa Stäng
2016-04-01 Enzymatica Enzymatica completes acquisition of Zymetech and includes new board members and representative to the nomination committee Pressreleaser Visa Stäng
2016-04-01 Enzymatica Enzymatica slutför förvärvet av Zymetech med tillträde för nya styrelseledamöter och representant i valberedningen Pressreleaser Ladda ner | Visa Stäng
2016-03-24 Enzymatica Tillförordnad CFO för Enzymatica utsedd Pressreleaser Ladda ner | Visa Stäng
2016-03-24 Enzymatica Acting CFO of Enzymatica appointed Pressreleaser Ladda ner | Visa Stäng
2016-03-17 Enzymatica Enzymatica AB: Uppdaterad tidsplan för förvärvet av Zymetech och företrädesemissionen Pressreleaser Visa Stäng
2016-03-17 Enzymatica Enzymatica AB: Updated time plan for the acquisition of Zymetech and the rights issue Pressreleaser Visa Stäng
2016-03-15 Enzymatica Enzymatica announces new dates for its financial information Pressreleaser Visa Stäng
2016-03-15 Enzymatica Enzymatica offentliggör nya datum för den finansiella informationen Pressreleaser Visa Stäng
2016-03-15 Enzymatica Kallelse till extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2016-03-15 Enzymatica NOTICE OF EXTRAORDINARY SHAREHOLDERS MEETING IN ENZYMATICA AB (PUBL) Pressreleaser Visa Stäng
2016-03-15 Enzymatica Styrelsen i Enzymatica beslutar om företrädesemission om 60 miljoner SEK Pressreleaser Visa Stäng
2016-03-15 Enzymatica The board of directors in Enzymatica has resolved on a rights issue of SEK 60 million Pressreleaser Ladda ner | Visa Stäng
2016-02-18 Enzymatica Enzymatica: EP Access - Förvärvar Zymetech Pressreleaser Visa Stäng
2016-02-16 Enzymatica Enzymatica AB: Strong growth in 2015 and acquisition for international expansion Pressreleaser Ladda ner | Visa Stäng
2016-02-15 Enzymatica Bulletin from the extraordinary shareholders' meeting in Enzymatica Pressreleaser Ladda ner | Visa Stäng
2016-02-15 Enzymatica Kommuniké från extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2016-02-15 Enzymatica Enzymatica AB: Stark tillväxt under 2015 och förvärv för internationell expansion Pressreleaser Visa Stäng
2016-02-03 Enzymatica Enzymatica tidigarelägger sin bokslutskommuniké 2015 Pressreleaser Ladda ner | Visa Stäng
2016-02-03 Enzymatica Enzymatica moves forward its year-end report for 2015 Pressreleaser Ladda ner | Visa Stäng
2016-01-28 Enzymatica NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB (PUBL) Pressreleaser Visa Stäng
2016-01-28 Enzymatica Kallelse till extra bolagsstämma i Enzymatica AB (publ) Pressreleaser Visa Stäng
2016-01-28 Enzymatica Enzymatica signs acquisition agreement and prepares for international expansion with new share issue Pressreleaser Visa Stäng
2016-01-28 Enzymatica Enzymatica ingår avtal om förvärv och förbereder internationell expansion genom nyemission Pressreleaser Ladda ner | Visa Stäng
2015-11-12 Enzymatica Enzymatica tecknar distributionssavtal med Esteve i Spanien Pressreleaser Visa Stäng
2015-11-12 Enzymatica Enzymatica signs distribution agreement with Esteve in Spain Pressreleaser Visa Stäng
2015-11-10 Enzymatica Enzymatica tecknar distributionsavtal med Tamro för den finska marknaden Pressreleaser Visa Stäng
2015-11-10 Enzymatica Enzymatica signs distribution agreement with Tamro for the Finnish market Pressreleaser Visa Stäng
2015-10-26 Enzymatica Enzymatica: EP Access - Fler kliniska studier är på gång Pressreleaser Visa Stäng
2015-10-20 Enzymatica Enzymatica AB: Delårsrapport för Enzymatica AB (publ) januari-september 2015 Rapporter Visa Stäng
2015-10-16 Enzymatica Enzymatica stärker närvaron i Storbritannien genom samarbete med apotekskedjan Lloyds Pressreleaser Visa Stäng
2015-10-16 Enzymatica Enzymatica strengthens its presence in the UK through collaboration with the Lloyds pharmacy chain Pressreleaser Visa Stäng
2015-08-04 Enzymatica Enzymatica: EP Access - Hemmamarknaden fortsätter att leverera Pressreleaser Visa Stäng
2015-07-21 Enzymatica Enzymatica: Delårsrapport för Enzymatica AB (publ) januari-juni 2015 Rapporter Visa Stäng
2015-06-15 Enzymatica Enzymatica ringde in bolaget på Nasdaq First North Pressreleaser Visa Stäng
2015-06-15 Enzymatica Enzymatica rang in the company at Nasdaq First North Pressreleaser Visa Stäng
2015-06-10 Enzymatica Enzymatica approved for listing on Nasdaq First North - trading to start June 15, 2015 Pressreleaser Ladda ner | Visa Stäng
2015-06-10 Enzymatica Enzymatica har godkänts för listning på Nasdaq First North - handelsstart den 15 juni 2015 Pressreleaser Ladda ner | Visa Stäng
2015-04-21 Enzymatica Enzymatica: Kommuniké från årsstämma i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2015-04-21 Enzymatica Enzymatica: Delårsrapport för Enzymatica AB (publ) januari-mars 2015 Pressreleaser Ladda ner | Visa Stäng
2015-04-16 Enzymatica Enzymatica: Valberedningen i Enzymatica lämnar reviderat styrelseförslag som stöds av bolagets huvudägare Pressreleaser Ladda ner | Visa Stäng
2015-04-09 Enzymatica Enzymatica: Enzymatica: Meddelande angående förslag inför årsstämma Pressreleaser Ladda ner | Visa Stäng
2015-04-08 Enzymatica Enzymatica: Valberedningens förslag till styrelse Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

16 Feb 2017 | Bokslutskommuniké 2016
20 Apr 2017 | Årsstämma 2016
21 Apr 2017 | Årligutdelning 2017
20 Jul 2017 | Kvartalsrapport 2017-Q2
1 Nov 2017 | Kvartalsrapport 2017-Q3
14 Feb 2018 | Bokslutskommuniké 2017
26 Apr 2018 | Årsstämma 2017
26 Apr 2018 | Kvartalsrapport 2018-Q1
27 Apr 2018 | Årligutdelning
17 Jul 2018 | Kvartalsrapport 2018-Q2
31 Oct 2018 | Kvartalsrapport 2018-Q3
19 Feb 2019 | Bokslutskommuniké 2018
7 May 2019 | Årsstämma 2018
7 May 2019 | Kvartalsrapport 2019-Q1
8 May 2019 | Årligutdelning
17 Jul 2019 | Kvartalsrapport 2019-Q2
13 Feb 2020 | Bokslutskommuniké 2019
5 May 2020 | Årsstämma 2019
5 May 2020 | Kvartalsrapport 2020-Q1
6 May 2020 | Årligutdelning
16 Jul 2020 | Kvartalsrapport 2020-Q2
3 Nov 2020 | Kvartalsrapport 2020-Q3
18 Feb 2021 | Bokslutskommuniké 2020
29 Apr 2021 | Kvartalsrapport 2021-Q1
5 May 2021 | Årsstämma 2020
6 May 2021 | Årligutdelning
16 Jul 2021 | Kvartalsrapport 2021-Q2
18 Oct 2021 | Extrastämma 2021
2 Nov 2021 | Kvartalsrapport 2021-Q3
17 Feb 2022 | Bokslutskommuniké 2021
28 Apr 2022 | Årsstämma 2021
28 Apr 2022 | Kvartalsrapport 2022-Q1
29 Apr 2022 | Årligutdelning
19 Jul 2022 | Kvartalsrapport 2022-Q2
2 Nov 2022 | Kvartalsrapport 2022-Q3
17 Feb 2023 | Bokslutskommuniké 2022